Narcolepsy Therapeutics Market Size Worth $7.75 Billion By 2032 | CAGR: 9.5%

The global narcolepsy therapeutics market size is expected to reach USD 7.75 billion by 2032, according to a new study by Polaris Market Research. The report “Narcolepsy Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Type (Cataplexy, Narcolepsy without Cataplexy, Secondary Narcolepsy); By Product; By Region; Segment Forecast, 2024 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Narcolepsy therapeutics market is driven by several factors, including increasing awareness and diagnosis of narcolepsy, the availability of effective treatments, and the development of new medications, drive market growth. Treatments for narcolepsy include stimulants to promote wakefulness, sodium oxybate to improve nighttime sleep and reduce cataplexy, and antidepressants to manage cataplexy and other symptoms.

Recent developments in the narcolepsy therapeutics market, such as the approval of new medications and formulations, the acquisition of existing drugs by companies, and the ongoing research and development of new treatments, are expected to drive market growth.

For example, the approval of Xywav (calcium, magnesium, potassium, and sodium oxybates) and Wakix (pitolisant) by the U.S. Food and Drug Administration (FDA) in 2020, and the acquisition of Sunosi (solriamfetol) by Axsome Therapeutics Inc. in 2021, are expected to increase the availability of effective treatments for narcolepsy.

Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/global-narcolepsy-therapeutics-market/request-for-sample

The increasing use of telemedicine and digital health technologies to improve access to healthcare and support remote monitoring and management of patients with narcolepsy is expected to further drive market growth.

Narcolepsy Therapeutics Market Report Highlights

• cataplexy segment is expected to dominate the narcolepsy therapeutics market over the forecast period due to increase in the demand for cataplexy treatment and increased prevalence of the narcolepsy.
• Sodium Oxybate segment held a largest market share and will continue the dominance over the forecast period, due to a most commonly prescribed medicine for the cataplexy treatment.
• North America dominates the global market due to the prevalence of the narcolepsy is highest in this region and FDA has approved several medications for the treatment of narcolepsy.
• The global key market players include Addrenex Pharmaceuticals, Cephalon, Inc., Arena Pharmaceuticals, Inc., Ligand Pharmaceuticals, Inc., BIOPROJET, Inc., Evotec AG, Graymark Healthcare, Inc., Hypnion, Inc., Jazz Pharmaceuticals, Inc., and Teva Pharmaceutical Industries Ltd.

Polaris Market Research has segmented the Narcolepsy Therapeutics market report based on type, product, and region:

Narcolepsy Therapeutics, Type Outlook (Revenue - USD Billion, 2019 - 2032)

• Cataplexy
• Narcolepsy without Cataplexy
• Secondary Narcolepsy

Narcolepsy Therapeutics, Product Outlook (Revenue - USD Billion, 2019 - 2032)

• Sodium Oxybate
• Central Nervous System Stimulants
• Selective Serotonin Reuptake Inhibitor
• Tricyclic Antidepressants

Narcolepsy Therapeutics, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

• North America

• U.S.
• Canada

• Europe

• Germany
• UK
• France
• Italy
• Spain
• Russia
• Netherlands

• Asia Pacific

• China
• India
• Japan
• South Korea
• Indonesia
• Malaysia

• Latin America

• Argentina
• Brazil
• Mexico

• Middle East & Africa

• UAE
• Saudi Arabia
• Israel
• South Africa